Back to top
more

Biofrontera Inc. (BFRI)

(Delayed Data from NSDQ)

$0.95 USD

0.95
88,363

-0.07 (-6.86%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $0.92 -0.03 (-3.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

by Zacks Equity Research

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -22.22% and 6.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of 10.87% and 123.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Tops Q4 Earnings Estimates

by Zacks Equity Research

Vericel (VCEL) delivered earnings and revenue surprises of 26.67% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 25% and 10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -21.43% and 76.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Biofrontera Inc. (BFRI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to Buy

by Zacks Equity Research

Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Biofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -19.46% and 0.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 8.33% and 44.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -4% and 25.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -29.41% and 5.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 0% and 5.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -1.45% and 30.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?